Drugs that contain Lanthanum Carbonate
1. List of Fosrenol drug patents
FOSRENOL's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(1 year, 2 months from now) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 2 months from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(7 years from now) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(7 years from now) | |
Do you want to check out FOSRENOL patents from before 2022?
Market Authorisation Date: 24 September, 2014
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER;ORAL
How can I launch a generic of FOSRENOL before it's patent expiration?
More Information on Dosage
FOSRENOL family patents
14
United States
7
Japan
6
European Union
5
Denmark
4
Spain
4
Poland
4
China
4
Canada
4
Cyprus
4
Portugal
4
Australia
4
Slovenia
3
Brazil
3
EA
3
Korea, Republic of
2
Austria
2
Germany
2
Norway
2
South Africa
2
Hungary
1
IB
1
Hong Kong
1
Iceland
1
Czech Republic
1
Singapore
1
Argentina
1
New Zealand
1
Peru
1
Israel
1
Taiwan
1
Mexico
1
Finland
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic